Logo image of MIRA

MIRA PHARMACEUTICALS INC (MIRA) Stock Fundamental Analysis

NASDAQ:MIRA - Nasdaq - US60458C1045 - Common Stock - Currency: USD

1.1  -0.01 (-0.9%)

After market: 1.12 +0.02 (+1.82%)

Fundamental Rating

2

Overall MIRA gets a fundamental rating of 2 out of 10. We evaluated MIRA against 194 industry peers in the Pharmaceuticals industry. While MIRA has a great health rating, there are worries on its profitability. MIRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIRA has reported negative net income.
MIRA had a negative operating cash flow in the past year.
MIRA Yearly Net Income VS EBIT VS OCF VS FCFMIRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of MIRA (-263.45%) is worse than 92.97% of its industry peers.
Looking at the Return On Equity, with a value of -314.53%, MIRA is doing worse than 76.76% of the companies in the same industry.
Industry RankSector Rank
ROA -263.45%
ROE -314.53%
ROIC N/A
ROA(3y)-376.79%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRA Yearly ROA, ROE, ROICMIRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MIRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRA Yearly Profit, Operating, Gross MarginsMIRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

MIRA has more shares outstanding than it did 1 year ago.
MIRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MIRA Yearly Shares OutstandingMIRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M
MIRA Yearly Total Debt VS Total AssetsMIRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 1M 2M 3M 4M

2.2 Solvency

MIRA has an Altman-Z score of 1.46. This is a bad value and indicates that MIRA is not financially healthy and even has some risk of bankruptcy.
MIRA has a Altman-Z score of 1.46. This is in the better half of the industry: MIRA outperforms 63.24% of its industry peers.
MIRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.46
ROIC/WACCN/A
WACCN/A
MIRA Yearly LT Debt VS Equity VS FCFMIRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M 4M -4M

2.3 Liquidity

MIRA has a Current Ratio of 6.11. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
MIRA has a better Current ratio (6.11) than 70.81% of its industry peers.
MIRA has a Quick Ratio of 6.11. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
MIRA has a Quick ratio of 6.11. This is in the better half of the industry: MIRA outperforms 72.97% of its industry peers.
Industry RankSector Rank
Current Ratio 6.11
Quick Ratio 6.11
MIRA Yearly Current Assets VS Current LiabilitesMIRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

MIRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.66%, which is quite impressive.
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 6.44% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.24%
EPS Next 2Y13.11%
EPS Next 3Y6.44%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIRA Yearly Revenue VS EstimatesMIRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M 250M
MIRA Yearly EPS VS EstimatesMIRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRA. In the last year negative earnings were reported.
Also next year MIRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRA Price Earnings VS Forward Price EarningsMIRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRA Per share dataMIRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.11%
EPS Next 3Y6.44%

More info and screens

0

5. Dividend

5.1 Amount

MIRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRA PHARMACEUTICALS INC

NASDAQ:MIRA (2/21/2025, 8:00:01 PM)

After market: 1.12 +0.02 (+1.82%)

1.1

-0.01 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners6.76%
Inst Owner Change34.89%
Ins Owners6.42%
Ins Owner Change0%
Market Cap18.22M
Analysts82.5
Price Target12.33 (1020.91%)
Short Float %4.62%
Short Ratio1.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.8%
Min EPS beat(2)-7.84%
Max EPS beat(2)11.45%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)-29.41%
EPS NQ rev (3m)-46.67%
EPS NY rev (1m)-5.36%
EPS NY rev (3m)-5.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB 5.1
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -263.45%
ROE -314.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-376.79%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.11
Quick Ratio 6.11
Altman-Z 1.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y13.24%
EPS Next 2Y13.11%
EPS Next 3Y6.44%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.83%
EBIT Next 3Y305.86%
EBIT Next 5YN/A
FCF growth 1Y19.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.13%
OCF growth 3YN/A
OCF growth 5YN/A